TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00534144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose injection, USP
Description: iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium ferric gluconate complex in sucrose injection
Description: sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
Study: NCT02518113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study: NCT03074890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application Protocol
Description: Application lMassive Transfusion Protocol
Study: NCT04037267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic intraventricular evacuation surgery
Description: According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
Study: NCT02518113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally
Study: NCT04037267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic intraventricular evacuation surgery
Description: According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
Study: NCT00551590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: placebo PO (placebo control for sitagliptin) for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: placebo PO (placebo control for sitagliptin) for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin tablet
Description: Sitagliptin 100 mg PO for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin tablet
Description: Sitagliptin 100 mg PO for three days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Saline IV (placebo control for exendin(9-39)) on two consecutive study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline infusion
Description: Saline IV (placebo control for exendin(9-39)) on two consecutive study days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin(9-39) infusion
Description: Exendin(9-39) IV on two consecutive study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exendin(9-39) infusion
Description: Exendin(9-39) IV on two consecutive study days.
Study: NCT02518113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally
Study: NCT05261919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture manipulation
Description: The investigator used directional supplementation and draining manipulation. The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.
Study: NCT01446757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The intervention group
Description: Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: No intervention
Study: NCT00119210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04864288

Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves

Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves
Study: NCT02518113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02521207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study: NCT03190746

Intervention type: DIAGNOSTIC_TEST
Intervention: TaqMan SNP analysis
Description: TaqMan SNP analysis of the YWHAH gene
Study: NCT04107987

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reglicem
Description: Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00698945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Istalol and Optive
Description: Istalol: one drop a day for 28 days Optive: one drop a day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alphagan
Description: Alphagan: two drops a day for 28 days
Study: NCT00607685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil with hyaluronic acid
Description: Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 Fluorouracil
Description: Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
Study: NCT05180929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual M1-tDCS
Description: In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a-tDCS over contralesional PMC
Description: In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
Study: NCT03382379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation (tDCS)
Description: Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
Study: NCT03674372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion (FETO)
Description: This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion (FETO)
Description: This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion (FETO)
Description: This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).
Study: NCT01877837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Adjusted Ideal Body Weight Formula: AIBW = IBW + \[(0.4) x (ABW - IBW)\]~b) Medications~i.) Alemtuzumab I. Hb S% must be \< or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued \>48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. \*Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Infusion of Hematopoietic Stem Cells
Study: NCT00153881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles).
Study: NCT00872677

Intervention type: BEHAVIORAL
Intervention: Diet
Description: Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.

Intervention type: BEHAVIORAL
Intervention: Diet
Description: Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.

Intervention type: OTHER
Intervention: Spiritual counseling
Description: Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
Study: NCT01900197

Intervention type: DRUG
Intervention: 10% Iron Isomaltoside 1000
Description: Administered according to local routines and product labeling in doses at the doctors discretion
Study: NCT01458431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: continuous levobupivacaine subfascial infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: continuous NaCl subfascial infusion
Study: NCT00423943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: 200 milligrams daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: capsule containing placebo
Study: NCT03980600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibDex wound dressing
Description: Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFC wound dressing Types 1-3
Description: Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprathel (comparator)
Description: Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
Study: NCT03611413

Intervention type: PROCEDURE
Intervention: ERAS care
Description: ERAS PROTOCOL
Study: NCT02590705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: surface anesthesia with lidocaine
Study: NCT01458639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon-133 Ventilation Planar imaging
Description: Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
Study: NCT04388683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
Study: NCT03960216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Supragingival Prophylaxis
Description: Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
Study: NCT00294203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa group
Description: Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
Study: NCT01299870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AED treatment plus placebo
Description: Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keishibukuryogan
Description: Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
Study: NCT05255575

Intervention type: DRUG
Intervention: Ertapenem
Description: Patients will receive ertapenem therapy.
Study: NCT04072042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib monotherapy
Description: patients will receive Apatinib 250mg tablet by mouth, bid.
Study: NCT02416843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of a mixed meal
Description: Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
Study: NCT04397991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients will receive nebulised furosemide solution 1 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive nebulised 0.9% saline
Study: NCT00433940

Intervention type: DRUG
Intervention: Prednisolone
Description: Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
Study: NCT00852033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
Study: NCT02416843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of a mixed meal
Description: Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of a mixed meal
Description: Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
Study: NCT02859259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 (1 tablet at 600 mg)
Description: BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 (4 tablets at 150 mg each tablet)
Description: BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
Study: NCT03056417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Complete Health Improvement Program
Description: The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
Study: NCT01839435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient surgery
Study: NCT05448339

Intervention type: COMBINATION_PRODUCT
Intervention: PVHA or TACE
Description: PVHA or TACE

Intervention type: COMBINATION_PRODUCT
Intervention: PVHA or TACE
Description: PVHA or TACE
Study: NCT00852033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Based Intervention plus booster
Description: The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.